238 related articles for article (PubMed ID: 21232659)
1. Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities.
Minter AR; Simpson H; Weiss BM; Landgren O
Semin Hematol; 2011 Jan; 48(1):55-65. PubMed ID: 21232659
[TBL] [Abstract][Full Text] [Related]
2. Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis.
Gámez B; Edwards CM
Curr Osteoporos Rep; 2018 Dec; 16(6):635-641. PubMed ID: 30229522
[TBL] [Abstract][Full Text] [Related]
3. Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.
Kristinsson SY; Minter AR; Korde N; Tan E; Landgren O
Expert Rev Mol Diagn; 2011 Jul; 11(6):593-603. PubMed ID: 21745013
[TBL] [Abstract][Full Text] [Related]
4. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
[TBL] [Abstract][Full Text] [Related]
6. The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
Babarović E; Valković T; Budisavljević I; Balen I; Štifter S; Duletić-Načinović A; Lučin K; Jonjić N
Pathol Res Pract; 2016 Jun; 212(6):509-16. PubMed ID: 26997492
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
8. MGUS to myeloma: a mysterious gammopathy of underexplored significance.
Dhodapkar MV
Blood; 2016 Dec; 128(23):2599-2606. PubMed ID: 27737890
[TBL] [Abstract][Full Text] [Related]
9. Multiple myeloma in the marrow: pathogenesis and treatments.
Fairfield H; Falank C; Avery L; Reagan MR
Ann N Y Acad Sci; 2016 Jan; 1364(1):32-51. PubMed ID: 27002787
[TBL] [Abstract][Full Text] [Related]
10. Myelomagenesis: capturing early microenvironment changes.
Korde N; Maric I
Semin Hematol; 2011 Jan; 48(1):13-21. PubMed ID: 21232654
[TBL] [Abstract][Full Text] [Related]
11. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
Golombick T; Diamond TH; Manoharan A; Ramakrishna R
Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
[TBL] [Abstract][Full Text] [Related]
12. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
[TBL] [Abstract][Full Text] [Related]
13. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?
Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR
Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571
[TBL] [Abstract][Full Text] [Related]
14. Molecular imaging in myeloma precursor disease.
Mena E; Choyke P; Tan E; Landgren O; Kurdziel K
Semin Hematol; 2011 Jan; 48(1):22-31. PubMed ID: 21232655
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; Rajkumar SV
Curr Hematol Malig Rep; 2010 Apr; 5(2):62-9. PubMed ID: 20425398
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.
Zingone A; Kuehl WM
Semin Hematol; 2011 Jan; 48(1):4-12. PubMed ID: 21232653
[TBL] [Abstract][Full Text] [Related]
17. Prevention of progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV
Clin Cancer Res; 2009 Sep; 15(18):5606-8. PubMed ID: 19737944
[TBL] [Abstract][Full Text] [Related]
18. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
[TBL] [Abstract][Full Text] [Related]
19. MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS).
Xiao R; Cerny J; Devitt K; Dresser K; Nath R; Ramanathan M; Rodig SJ; Chen BJ; Woda BA; Yu H
Am J Surg Pathol; 2014 Jun; 38(6):776-83. PubMed ID: 24705315
[TBL] [Abstract][Full Text] [Related]
20. Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance.
Kristinsson SY; Björkholm M; Schulman S; Landgren O
Semin Hematol; 2011 Jan; 48(1):46-54. PubMed ID: 21232658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]